Bone Biologics (NASDAQ:BBLG) Shares Down 0.5% – Should You Sell?

Bone Biologics Corp. (NASDAQ:BBLG)’s share price fell 0.5% during trading on Wednesday . The stock traded as low as $1.9246 and last traded at $2.10. 43,801 shares were traded during trading, an increase of 8% from the average session volume of 40,407 shares. The stock had previously closed at $2.11.

Analyst Upgrades and Downgrades

Several research firms have weighed in on BBLG. Weiss Ratings restated a “sell (e+)” rating on shares of Bone Biologics in a report on Monday. Wall Street Zen raised Bone Biologics from a “sell” rating to a “hold” rating in a research note on Sunday, September 28th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has an average rating of “Sell”.

Bone Biologics Trading Down 0.5%

The firm has a 50-day moving average of $2.02 and a two-hundred day moving average of $2.81. The firm has a market cap of $3.78 million, a price-to-earnings ratio of -0.58 and a beta of 0.75.

Bone Biologics (NASDAQ:BBLG) last issued its quarterly earnings results on Friday, November 14th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($1.23) by $0.86. As a group, equities analysts anticipate that Bone Biologics Corp. will post -5 EPS for the current year.

Bone Biologics Company Profile

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.